Clinical trials: Hip Surgeries
Total Hip Replacement Surgery
Pharmacokinetic Study of the Penetration of Ceftobiprole in the Bone
This study is being performed to measure the amount of the antibiotic ceftobiprole (study drug) found in the bone and blood after receiving one dose prior to your elective hip replacement surgery.
- Trial name
- NCT00771524
- Testing
- Ceftobiprole
- Volunteers
- 22 people
- Sponsor
- Basilea Pharmaceutica
Arthroplasty, Replacement, Prevention of Venous Thromboembolism
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
To supplement the current evidence of the effect of Pradaxa® (dabigatran etexilate) on coagulation parameters, including a calibrated thrombin time test, in patients with moderate renal impairment undergoing elective total hip…
- Conditions
- Arthroplasty, Replacement, Prevention of Venous Thromboembolism, Moderate Renal Impairment (CrCl 30-50 mL/Min)
- Trial name
- NCT01184989
- Testing
- Dabigatran etexilate
- Where
- 10 sites in Austria, Canada and 4 more
- Volunteers
- 142 people
- Sponsor
- Boehringer Ingelheim
Primary Arthritis, Secondary Arthritis
A Multi-centre Study to Assess the Long-term Performance of the Silent Hip™ in Primary Total Hip Replacement Surgery
The purpose of this study is to monitor the performance and of the Silent Hip™ in the treatment of patients with hip joint disease requiring a total hip replacement.
- Trial name
- NCT01383824
- Testing
- Silent™ Hip
- Where
- 9 sites in Denmark, Germany and 3 more
- Volunteers
- 89 people
- Sponsor
- DePuy International
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery
The primary objective is to evaluate the efficacy of once daily (QD) subcutaneous (SC) injections of Semuloparin sodium (AVE5026) versus placebo for 3 additional weeks following an initial 7 to 10-day venous thromboprophylaxis…
- Trial name
- SAVE-HIP3 (NCT00709904)
- Testing
- Open-label Semuloparin sodium, Semuloparin sodium
- Where
- 16 sites in United States, Belarus and 14 more
- Volunteers
- 469 people
- Sponsor
- Sanofi
Hip Fracture Surgery
A Non-inferiority Study Comparing Two Heparin Sodium Preparations in Hip Fracture Surgery
The primary objective and endpoints of the study is compare the efficacy of two products containing heparin sodium, evaluating if the formulation produced by Eurofarma can be considered non-inferior to the reference product.
- Trial name
- HEP-SC (NCT01352039)
- Testing
- Heparin Sodium - Eurofarma, Heparin Sodium - APP Pharmaceuticals
- Where
- 5 sites in Brazil
- Volunteers
- 544 people
- Sponsor
- Eurofarma Laboratorios S.A.
Venous Thromboembolism
Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.
- Trial name
- NCT00329628
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 215 sites in United States, Argentina and 26 more
- Volunteers
- 4,541 people
- Sponsor
- Bayer
Total Knee Replacement, Total Hip Replacement
New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery
LY517717 (a capsule given by mouth) is a blood thinner that may prevent blood clots from forming in the legs and may prevent those blood clots from traveling to the lungs.
- Trial name
- NCT00074828
- Testing
- LY517717, enoxaparin
- Where
- 8 sites in Australia, Austria and 6 more
- Volunteers
- 511 people
- Sponsor
- Eli Lilly and Company
Bone Diseases, Infectious
Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery
Debio 1450 is being developed for the treatment of staph (staphylococcal) infections. How fast and completely an antibiotic penetrates into bone is used to determine how effective it might be to treat infections related to bones…
- Trial name
- NCT02726438
- Testing
- Debio 1450
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Debiopharm International SA
Fracture Healing
Study To Assess FRacTure Healing With SclerosTin Antibody - Hip
This is an international, multi-center study to determine the efficacy, safety, and tolerability of romosozumab (AMG 785) in adults with a fresh unilateral hip fracture, status post surgical fixation.
- Trial name
- STARTT-Hip (NCT01081678)
- Testing
- Romosozumab
- Where
- 99 sites in United States, Argentina and 22 more
- Volunteers
- 332 people
- Sponsor
- Amgen
Osteoarthritis(Primary)
A Randomised Multi-centre Study to Compare the Short-term Outcomes of Minimally Invasive and Conventional Surgery in Primary Total Hip Replacement
The purpose of this study is to compare the short-term outcomes of two surgical techniques, minimally invasive and conventional, when used in the treatment of patients with hip joint disease requiring a total hip replacement.
- Trial name
- NCT00208416
- Testing
- DePuy MI System, Conventional surgical technique
- Where
- 2 sites in United Kingdom
- Volunteers
- 58 people
- Sponsor
- DePuy International
Hip Arthritis
Post Market, Retrospective Study to Evaluate Patients Implanted With Medacta Versafit Cup DM ™️ 2 Years Post-op
This is a post-market, retrospective with one prospective visit, multi- center study, designed to assess the clinical outcomes, surgical details including Anterior or Posterior surgical approach, and collect all complication data…
- Trial name
- NCT03897387
- Where
- 3 sites in United States
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- Medacta USA
Venous Thromboembolism
Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty
The primary objective of the trial is to demonstrate non-inferiority of 220 mg oral dabigatran etexilate compared to 40 mg subcutaneous enoxaparin administered once daily.
- Trial name
- NCT00657150
- Testing
- Enoxaparin, Dabigatran etexilate
- Where
- 108 sites in United States, Australia and 17 more
- Volunteers
- 2,055 people
- Sponsor
- Boehringer Ingelheim
Thromboembolism
Hip Fracture Study of GSK576428 (Fondaparinux Sodium)
This study is requested by PMDA to confirm the efficacy and the safety for HFS.
- Trial name
- NCT00320424
- Testing
- Fondaparinux
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Hip Surgery
Post Market Clinical Follow-up of Hip Surgery Using FH ORTHO Company Medical Devices.
The objective of this observatory is to generate additional real life clinical data in accordance with local regulation (i.e. Post-Market Clinical Follow-up (PMCF) study, a study carried out following the European Conformity (CE)…
- Trial name
- HipFHOrtho (NCT05966220)
- Testing
- Hip surgery with FH Ortho devices
- Where
- 5 sites in France
- Volunteers
- 800 people
- Sponsor
- FH ORTHO
Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee
Study Measuring the Effects of Patient Data for Total Hip and Total Knee Arthroplasty Patients Using an APP Based Sensor for Home Exercise Performance Before and After Operation
Multicenter, Prospective, Randomized, Comparative Study Measuring the Effects on Clinical Outcomes, Patient Satisfaction, Costs and Benefits of Combined Pre-, Intra- and Postoperative Patient Data for THA and TKA Patients Using…
- Conditions
- Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee, Clinical Outcome, Patient Satisfaction
- Trial name
- ORTHOPATH (NCT05182320)
- Testing
- OrthoPath, Control
- Where
- 2 sites in Germany
- Sponsor
- Aesculap AG
Arthropathy of Knee, Arthropathy of Hip
Nirvana Super Pro Supplementation in Orthopedic Surgery Patients
The purpose of this study is to investigate orthopedic patients undergoing either a total hip replacement (THR) or total knee arthroplasty (TKR) using two dietary supplements, PREPARE and RECOVER, and their recovery times…
- Trial name
- NCT06203691
- Testing
- Supplementation with Nirvana Super Pro Liquid Supplements, Non-Supplementation Group
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Nirvana Water Sciences Corp
Blood Loss, Surgical
Effect of Aprotinin on Transfusion Requirements and Blood Loss in Patients Undergoing Elective Primary Total Hip Replacement
The purpose of this study is to assess if aprotinin (BAY A0128), given intravenously during surgery, is safe and can help reduce the amount of bleeding and the need for a blood transfusion during hip replacement surgery.
- Trial name
- NCT00668031
- Testing
- Trasylol (Aprotinin, BAYA0128)
- Where
- 40 sites in United States, Canada and 1 more
- Volunteers
- 359 people
- Sponsor
- Bayer
Pain, Postoperative
Analgesic Efficacy, Safety and Tolerability of Two Paracetamol-Containing Solutions in Post-Surgical Hip Replacement Pain
The aim of the study is to evaluate the therapeutic efficacy, safety and local tolerability of two different paracetamol-containing solutions in postoperative total hip replacement.
- Trial name
- NCT00508495
- Testing
- Paracetamol (acetaminophen), Paracetamol 1% solution, 0.9% sodium chloride solution
- Where
- 8 sites in Hungary
- Volunteers
- 148 people
- Sponsor
- Baxter Healthcare Corporation
Primary Osteoarthritis, Post-traumatic Osteoarthritis of Hip Nos
Observational Study Evaluating Outcomes of Hip Arthroplasty Using Tornier Dual Mobility Acetabular Cup
The purpose of this study is to demonstrate the performance and reliability of Tornier "Dual Mobility Cup" used during primary total hip replacement or hip replacement revision surgery at least 24 months post-insertion.
- Conditions
- Primary Osteoarthritis, Post-traumatic Osteoarthritis of Hip Nos, Femur Head Necrosis, Femur Neck Fracture
- Trial name
- NCT02062450
- Testing
- Primary surgery with Dual Mobility Cup, Revision surgery with Dual Mobility Cup
- Volunteers
- 379 people
- Sponsor
- Stryker Trauma and Extremities
Hip Osteoarthritis, Avascular Necrosis
Insignia™ Hip Stem Outcomes Study
The objective of this study is to evaluate the safety and effectiveness of the Insignia™ Hip Stem for global market access and post-market clinical follow-up up to 10 years postoperative.
- Conditions
- Hip Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis, Post-traumatic Osteoarthritis
- Trial name
- NCT05144191
- Testing
- Insignia uncemented Hip Stem
- Where
- 11 sites in United States
- Volunteers
- 313 people
- Sponsor
- Stryker Orthopaedics